Abbvie Inc - Regenerative Healthcare - Stem Cells & ALS Thematic 10062024
Regenerative medicine remains an extremely exciting area of healthcare with vast investment potential. In spite of the usual setbacks in valuation...
404 Views
Microsoft: Growth Bulls Versus Value Bears
US Growth managers are relying on Microsoft to deliver an increasing proportion of the Growth within their portfolios. The cost of that growth is...
494 Views
Antengene: Gunning To Move Up in Line
This Insight provides an in-depth review of pre-revenue biotechnology Antegene that plans to list on the HKEX. We discuss the pipeline, market...
635 Views
(Mostly) Asia M&A: November 2019 Roundup
For the month of November, 21 new deals were discussed on Smartkarma with an overall announced deal size of ~US$75bn, helped in large part by...
777 Views
Allergan Plc Acquisition by AbbVie Inc. – A Botox Deal with Some Wrinkles
On June 25, 2019, Abbvie Inc (ABBV US) announced its acquisition of Botox-maker Allergan Plc (AGN US) in a $63 billion cash and stock deal in which...
892 Views